exemestane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
aromatase inhibitors 1122 107868-30-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aromasine
  • FCE 24304
  • exemestane
  • aromasin
a hormonal antineoplastic agent
  • Molecular weight: 296.41
  • Formula: C20H24O2
  • CLOGP: 3.28
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 34.14
  • ALOGS: -4.64
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.35 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,TTK 40
kinase-selectivity-class EIF2AK3,GRK2,MAP3K14 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.589 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.661 % High 1

Approvals:

DateAgencyCompanyOrphan
Oct. 21, 1999 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 2298.54 14.06 1172 53713 105698 90467864
Metastases to bone 1592.33 14.06 594 54291 24911 90548651
Metastases to liver 1326.60 14.06 538 54347 28269 90545293
Neoplasm progression 1075.26 14.06 529 54356 43957 90529605
Osteonecrosis of jaw 807.10 14.06 418 54467 38685 90534877
Disease progression 681.38 14.06 641 54244 155974 90417588
Metastases to lung 576.21 14.06 251 54634 15740 90557822
Breast cancer metastatic 524.08 14.06 231 54654 14901 90558661
Tumour marker increased 427.97 14.06 153 54732 5654 90567908
Metastases to lymph nodes 409.80 14.06 180 54705 11509 90562053
Pneumonitis 381.50 14.06 270 54615 43900 90529662
Pleural effusion 301.18 14.06 355 54530 111636 90461926
Mucosal inflammation 297.51 14.06 260 54625 57365 90516197
Bone pain 288.97 14.06 264 54621 61719 90511843
Metastases to skin 276.14 14.06 86 54799 2054 90571508
Breast cancer 256.50 14.06 232 54653 53529 90520033
PIK3CA-activated mutation 232.13 14.06 66 54819 1138 90572424
Stomatitis 226.53 14.06 508 54377 274190 90299372
Metastases to pleura 225.91 14.06 73 54812 1971 90571591
Lymphoedema 216.62 14.06 123 54762 13630 90559932
Neutropenia 214.18 14.06 441 54444 224463 90349099
Drug ineffective 207.80 14.06 325 54560 1383973 89189589
Systemic lupus erythematosus 203.72 14.06 3 54882 361893 90211669
Breast cancer recurrent 203.47 14.06 88 54797 5415 90568147
Osteonecrosis 202.78 14.06 150 54735 26091 90547471
Maternal exposure during pregnancy 202.62 14.06 3 54882 360060 90213502
Hot flush 182.53 14.06 202 54683 59286 90514276
Metastases to spine 179.31 14.06 72 54813 3671 90569891
Bone lesion 174.80 14.06 83 54802 6354 90567208
Ascites 174.64 14.06 178 54707 47562 90526000
Bone disorder 173.81 14.06 130 54755 22990 90550572
Second primary malignancy 172.07 14.06 96 54789 10282 90563280
Palmar-plantar erythrodysaesthesia syndrome 170.42 14.06 139 54746 27884 90545678
Rheumatoid arthritis 164.73 14.06 15 54870 362599 90210963
Infusion related reaction 158.96 14.06 30 54855 416750 90156812
Carbohydrate antigen 15-3 increased 148.32 14.06 53 54832 1954 90571608
Metastases to central nervous system 146.25 14.06 105 54780 17437 90556125
Metastasis 145.16 14.06 72 54813 6065 90567497
Bone sequestrum 140.87 14.06 47 54838 1406 90572156
Therapeutic product effect decreased 139.09 14.06 7 54878 277564 90295998
Joint swelling 136.82 14.06 67 54818 503233 90070329
Glossodynia 136.70 14.06 17 54868 321762 90251800
Synovitis 136.30 14.06 19 54866 329733 90243829
Ejection fraction decreased 132.52 14.06 117 54768 26136 90547426
Interstitial lung disease 130.54 14.06 194 54691 76211 90497351
Off label use 129.64 14.06 299 54586 1101953 89471609
Hepatic lesion 129.58 14.06 65 54820 5608 90567954
Contraindicated product administered 128.72 14.06 20 54865 320119 90253443
Cough 123.64 14.06 496 54389 368466 90205096
Metastases to peritoneum 123.40 14.06 57 54828 4098 90569464
Psoriatic arthropathy 120.27 14.06 4 54881 228331 90345231
Neuropathy peripheral 119.13 14.06 259 54626 136711 90436851
Exposed bone in jaw 108.86 14.06 47 54838 2879 90570683
Arthropathy 108.55 14.06 43 54842 366199 90207363
Irritable bowel syndrome 107.98 14.06 4 54881 207444 90366118
Hyperglycaemia 107.22 14.06 143 54742 50827 90522735
Wound 104.97 14.06 27 54858 302953 90270609
Fatigue 101.63 14.06 1105 53780 1152918 89420644
Anaemia 100.86 14.06 452 54433 352350 90221212
Hormone receptor positive breast cancer 99.15 14.06 31 54854 750 90572812
Malignant pleural effusion 98.58 14.06 44 54841 2920 90570642
Abdominal discomfort 96.78 14.06 88 54797 477240 90096322
Folliculitis 96.78 14.06 7 54878 204346 90369216
Discomfort 95.89 14.06 24 54861 274311 90299251
Fibromyalgia 95.06 14.06 8 54877 206261 90367301
Gamma-glutamyltransferase increased 94.84 14.06 116 54769 37836 90535726
Epistaxis 94.27 14.06 178 54707 84947 90488615
Intentional product use issue 88.41 14.06 13 54872 216879 90356683
Mobility decreased 87.50 14.06 22 54863 250712 90322850
Leukopenia 85.91 14.06 189 54696 100521 90473041
Pseudocirrhosis 85.45 14.06 29 54856 915 90572647
Pleural neoplasm 84.78 14.06 24 54861 407 90573155
Myelosuppression 82.94 14.06 130 54755 53461 90520101
Gingival swelling 82.09 14.06 46 54839 4967 90568595
Skin toxicity 81.62 14.06 51 54834 6728 90566834
Blister 80.49 14.06 27 54858 254971 90318591
Tooth extraction 80.48 14.06 62 54823 11451 90562111
Hepatic enzyme increased 79.87 14.06 61 54824 360675 90212887
Lymphangiosis carcinomatosa 79.53 14.06 32 54853 1640 90571922
Device related thrombosis 79.11 14.06 34 54851 2059 90571503
Type 2 diabetes mellitus 78.76 14.06 14 54871 203230 90370332
Eastern Cooperative Oncology Group performance status worsened 78.27 14.06 33 54852 1906 90571656
Lymphadenopathy mediastinal 77.41 14.06 38 54847 3129 90570433
Treatment failure 77.27 14.06 44 54841 303884 90269678
White blood cell count decreased 75.68 14.06 248 54637 166861 90406701
Swelling 74.98 14.06 86 54799 418972 90154590
Aspartate aminotransferase increased 74.40 14.06 181 54704 102756 90470806
Metastases to chest wall 74.30 14.06 24 54861 647 90572915
Polyneuropathy 74.16 14.06 74 54811 19267 90554295
Blood creatinine increased 72.98 14.06 178 54707 101208 90472354
Haematotoxicity 71.66 14.06 60 54825 12475 90561087
Blood alkaline phosphatase increased 70.78 14.06 114 54771 47965 90525597
Metastases to pelvis 69.53 14.06 22 54863 554 90573008
Confusional state 69.36 14.06 79 54806 386126 90187436
Hepatic failure 68.01 14.06 101 54784 39627 90533935
Diarrhoea 66.81 14.06 864 54021 938326 89635236
Metastases to the mediastinum 66.68 14.06 22 54863 635 90572927
Hypersensitivity 66.53 14.06 108 54777 454569 90118993
Aphthous ulcer 64.18 14.06 65 54820 17222 90556340
Wheezing 62.63 14.06 33 54852 238047 90335515
Osteolysis 62.03 14.06 34 54851 3516 90570046
Oral pain 61.65 14.06 87 54798 32596 90540966
Weight increased 61.39 14.06 99 54786 417828 90155734
Invasive ductal breast carcinoma 61.08 14.06 45 54840 7773 90565789
Product use issue 58.67 14.06 68 54817 329851 90243711
Lung infiltration 57.72 14.06 58 54827 15224 90558338
Lymphadenopathy 57.35 14.06 101 54784 45674 90527888
Urticaria 57.20 14.06 63 54822 312671 90260891
Dysgeusia 55.83 14.06 108 54777 52452 90521110
Joint range of motion decreased 55.56 14.06 8 54877 135635 90437927
Injury 55.48 14.06 25 54860 197324 90376238
Osteitis 54.75 14.06 32 54853 3741 90569821
Metastases to adrenals 54.53 14.06 21 54864 957 90572605
Therapeutic product effect incomplete 53.83 14.06 25 54860 193871 90379691
Osteomyelitis 53.82 14.06 75 54810 27771 90545791
Sinusitis 52.53 14.06 79 54806 343009 90230553
Condition aggravated 51.78 14.06 186 54699 595359 89978203
Hypotension 51.71 14.06 73 54812 325324 90248238
Abdominal lymphadenopathy 50.27 14.06 20 54865 995 90572567
Gastrointestinal disorder 49.98 14.06 49 54836 256638 90316924
Overdose 49.22 14.06 17 54868 157692 90415870
Decreased appetite 49.20 14.06 393 54492 376147 90197415
Liver injury 48.90 14.06 21 54864 170546 90403016
Alanine aminotransferase increased 48.60 14.06 170 54715 118168 90455394
Jaw disorder 48.00 14.06 34 54851 5525 90568037
Oral cavity fistula 47.56 14.06 17 54868 627 90572935
Blood lactate dehydrogenase increased 47.39 14.06 68 54817 25864 90547698
Cardiac failure 46.44 14.06 159 54726 109337 90464225
Periodontitis 46.42 14.06 29 54856 3824 90569738
Product use in unapproved indication 46.27 14.06 83 54802 336153 90237409
Pulmonary mass 46.19 14.06 71 54814 28701 90544861
Blood glucose increased 45.49 14.06 144 54741 95102 90478460
Ill-defined disorder 45.23 14.06 28 54857 184863 90388699
Metastases to meninges 44.72 14.06 28 54857 3707 90569855
Peritoneal disorder 43.80 14.06 16 54869 629 90572933
Drug hypersensitivity 43.52 14.06 140 54745 463469 90110093
Asthenia 43.41 14.06 504 54381 533247 90040315
Contusion 43.34 14.06 53 54832 251163 90322399
Hepatic function abnormal 43.05 14.06 90 54795 46198 90527364
Pathological fracture 42.76 14.06 40 54845 9620 90563942
Intentional overdose 42.24 14.06 4 54881 93830 90479732
Facet joint syndrome 42.22 14.06 5 54880 98384 90475178
Gingival erythema 41.73 14.06 18 54867 1100 90572462
Adverse event 41.53 14.06 10 54875 117408 90456154
Superinfection 41.52 14.06 25 54860 3087 90570475
Obesity 41.45 14.06 7 54878 105500 90468062
Onychoclasis 41.43 14.06 35 54850 7364 90566198
Lip dry 41.24 14.06 6 54879 100949 90472613
Pain in jaw 40.83 14.06 90 54795 47895 90525667
Sequestrectomy 40.66 14.06 16 54869 773 90572789
Invasive lobular breast carcinoma 39.83 14.06 17 54868 1012 90572550
Medication error 39.77 14.06 3 54882 84649 90488913
Bone marrow infiltration 39.65 14.06 16 54869 826 90572736
Nasopharyngitis 39.57 14.06 121 54764 406983 90166579
Tumour marker abnormal 39.54 14.06 13 54872 371 90573191
Weight decreased 39.45 14.06 377 54508 379533 90194029
Dyspnoea 39.39 14.06 750 54135 880205 89693357
Blood bilirubin increased 38.66 14.06 83 54802 43387 90530175
Nail disorder 38.61 14.06 100 54785 58967 90514595
Metastases to soft tissue 38.35 14.06 12 54873 291 90573271
Musculoskeletal stiffness 38.33 14.06 76 54809 296456 90277106
Psoriasis 38.08 14.06 21 54864 147733 90425829
Lower respiratory tract infection 38.08 14.06 58 54827 250601 90322961
Injection site erythema 37.68 14.06 7 54878 98495 90475067
Product dose omission issue 37.49 14.06 75 54810 291612 90281950
Erysipelas 37.25 14.06 36 54849 9016 90564546
Peripheral swelling 36.54 14.06 128 54757 412978 90160584
Bursitis 36.49 14.06 17 54868 131637 90441925
Injection site pain 36.37 14.06 31 54854 173668 90399894
Migraine 36.30 14.06 37 54848 190355 90383207
Mouth ulceration 35.18 14.06 76 54809 39898 90533664
Metastases to abdominal wall 35.14 14.06 10 54875 173 90573389
Haemoglobin decreased 35.13 14.06 192 54693 161764 90411798
Hip arthroplasty 34.97 14.06 3 54882 76205 90497357
Creutzfeldt-Jakob disease 34.87 14.06 10 54875 178 90573384
Death 34.41 14.06 425 54460 456126 90117436
Peripheral venous disease 34.25 14.06 5 54880 83916 90489646
Wound infection 34.02 14.06 11 54874 106391 90467171
Fibrous histiocytoma 33.46 14.06 13 54872 607 90572955
Purulent discharge 33.25 14.06 27 54858 5378 90568184
Thrombocytopenia 32.99 14.06 228 54657 208497 90365065
Road traffic accident 32.90 14.06 12 54873 107614 90465948
Radiation skin injury 32.38 14.06 15 54870 1085 90572477
Axillary pain 31.88 14.06 19 54866 2302 90571260
Hospitalisation 31.88 14.06 19 54866 128081 90445481
Gingival recession 31.30 14.06 17 54868 1726 90571836
Mucosal dryness 31.18 14.06 21 54864 3146 90570416
Arthralgia 31.14 14.06 652 54233 777870 89795692
Nausea 30.95 14.06 885 54000 1109431 89464131
Recurrent cancer 30.87 14.06 19 54866 2440 90571122
Asthma 30.49 14.06 63 54822 242097 90331465
Osteopenia 30.44 14.06 52 54833 22950 90550612
Exostosis of jaw 30.36 14.06 15 54870 1252 90572310
Impaired healing 30.28 14.06 60 54825 234139 90339423
Metastases to abdominal cavity 30.14 14.06 12 54873 598 90572964
Pericardial effusion 30.12 14.06 68 54817 36765 90536797
Nail dystrophy 29.80 14.06 15 54870 1303 90572259
Pulmonary embolism 29.66 14.06 157 54728 130663 90442899
Gait inability 29.62 14.06 27 54858 146429 90427133
Recall phenomenon 29.51 14.06 13 54872 836 90572726
Oedema peripheral 29.30 14.06 261 54624 257654 90315908
Gingivitis 29.04 14.06 32 54853 9337 90564225
Protein total decreased 28.80 14.06 28 54857 7061 90566501
Myalgia 28.68 14.06 193 54692 174932 90398630
Carcinoid tumour pulmonary 28.40 14.06 11 54874 509 90573053
Skin lesion 28.37 14.06 67 54818 37298 90536264
Neoplasm recurrence 28.29 14.06 20 54865 3239 90570323
Pleural disorder 28.28 14.06 12 54873 704 90572858
Oral disorder 28.10 14.06 33 54852 10312 90563250
Adverse drug reaction 28.08 14.06 18 54867 116683 90456879
Dermatitis 27.79 14.06 49 54836 22171 90551391
General physical health deterioration 27.78 14.06 333 54552 354782 90218780
Serous cystadenocarcinoma ovary 27.73 14.06 6 54879 30 90573532
Nail infection 27.61 14.06 18 54867 2554 90571008
Product quality issue 27.57 14.06 7 54878 79318 90494244
Cardiomyopathy 27.16 14.06 46 54839 20160 90553402
Fall 26.93 14.06 176 54709 481634 90091928
Metastases to thorax 26.85 14.06 9 54876 273 90573289
Concomitant disease aggravated 26.84 14.06 34 54851 11484 90562078
Lower limb fracture 26.80 14.06 9 54876 85004 90488558
Lacrimation increased 26.79 14.06 54 54831 27008 90546554
Hepatic atrophy 26.67 14.06 9 54876 279 90573283
Blood phosphorus decreased 26.53 14.06 23 54862 5011 90568551
Feeding disorder 26.42 14.06 42 54843 17470 90556092
Periodontal disease 26.12 14.06 15 54870 1697 90571865
Congestive cardiomyopathy 26.12 14.06 27 54858 7327 90566235
Trigger finger 26 14.06 23 54862 5147 90568415
Excessive granulation tissue 25.80 14.06 12 54873 876 90572686
COVID-19 25.70 14.06 39 54846 168804 90404758
Hyperparathyroidism secondary 25.41 14.06 15 54870 1786 90571776
Blood phosphorus increased 25.37 14.06 21 54864 4297 90569265
Rib fracture 25.28 14.06 52 54833 26383 90547179
Debridement 24.73 14.06 13 54872 1236 90572326
Bradycardia 24.54 14.06 10 54875 83837 90489725
Pancreatic neoplasm 24.38 14.06 12 54873 994 90572568
Cholestasis 24.28 14.06 62 54823 36237 90537325
Breast cancer female 24.27 14.06 37 54848 14849 90558713
Loss of personal independence in daily activities 24.22 14.06 28 54857 136077 90437485
Mouth swelling 24.21 14.06 23 54862 5639 90567923
Red blood cell count decreased 23.91 14.06 72 54813 46279 90527283
Neoplasm malignant 23.85 14.06 59 54826 33821 90539741
Tumour marker decreased 23.67 14.06 6 54879 65 90573497
Toxicity to various agents 23.59 14.06 92 54793 287754 90285808
Uterine mass 23.46 14.06 9 54876 406 90573156
Musculoskeletal discomfort 23.35 14.06 44 54841 20947 90552615
Breast pain 23.09 14.06 30 54855 10388 90563174
Bone neoplasm 23.00 14.06 11 54874 855 90572707
Actinomycosis 23.00 14.06 12 54873 1124 90572438
Vulvovaginal dryness 22.94 14.06 18 54867 3413 90570149
Cell marker increased 22.92 14.06 8 54877 275 90573287
Hiccups 22.70 14.06 17 54868 3009 90570553
Spinal pain 22.67 14.06 37 54848 15730 90557832
Hallucination 22.58 14.06 6 54879 65953 90507609
Computerised tomogram abnormal 22.57 14.06 16 54869 2603 90570959
Skin mass 22.38 14.06 25 54860 7405 90566157
Hormone receptor positive HER2 negative breast cancer 22.36 14.06 8 54877 296 90573266
Pulmonary tumour thrombotic microangiopathy 21.88 14.06 6 54879 90 90573472
Platelet count decreased 21.85 14.06 150 54735 136819 90436743
Hypokalaemia 21.76 14.06 145 54740 130971 90442591
Multiple sclerosis relapse 21.61 14.06 3 54882 52302 90521260
Constipation 21.51 14.06 262 54623 280133 90293429
Diabetes mellitus 21.47 14.06 87 54798 64788 90508774
Dyspepsia 21.36 14.06 56 54829 198104 90375458
Sciatica 21.33 14.06 18 54867 101364 90472198
Radiation fibrosis 21.31 14.06 5 54880 38 90573524
Upper respiratory fungal infection 21.15 14.06 7 54878 204 90573358
Ear infection 20.95 14.06 8 54877 69767 90503795
Laryngitis 20.76 14.06 3 54882 50750 90522812
Incorrect dose administered 20.65 14.06 11 54874 78919 90494643
Radioisotope scan 20.64 14.06 4 54881 10 90573552
Fluid retention 20.63 14.06 14 54871 88077 90485485
Bone debridement 20.53 14.06 7 54878 224 90573338
Acne 20.44 14.06 50 54835 28457 90545105
Cancer pain 20.43 14.06 18 54867 4007 90569555
Muscle twitching 20.14 14.06 45 54840 24157 90549405
Abscess jaw 20.02 14.06 12 54873 1469 90572093
Back pain 20.01 14.06 286 54599 316889 90256673
Product administered at inappropriate site 19.95 14.06 18 54867 4133 90569429
Chronic myelomonocytic leukaemia 19.92 14.06 8 54877 408 90573154
Atrophic vulvovaginitis 19.75 14.06 13 54872 1874 90571688
Ageusia 19.53 14.06 35 54850 16041 90557521
Peripheral sensory neuropathy 19.52 14.06 26 54859 9224 90564338
Blood cholesterol increased 19.35 14.06 63 54822 207949 90365613
Ischaemic stroke 19.34 14.06 42 54843 22124 90551438
Anticipatory anxiety 19.34 14.06 11 54874 1222 90572340
Osteosclerosis 19.33 14.06 18 54867 4302 90569260
Fibrin D dimer increased 19.31 14.06 20 54865 5440 90568122
Cutaneous sarcoidosis 19.06 14.06 8 54877 457 90573105
Suicide attempt 19.02 14.06 11 54874 75388 90498174
Lymphangitis 18.75 14.06 10 54875 979 90572583
Neuromuscular toxicity 18.72 14.06 7 54878 294 90573268
Back injury 18.52 14.06 3 54882 46619 90526943
Lymphatic obstruction 18.49 14.06 4 54881 20 90573542
Hilar lymphadenopathy 18.43 14.06 11 54874 1337 90572225
Subclavian vein thrombosis 18.40 14.06 13 54872 2103 90571459
Injection site pruritus 18.23 14.06 5 54880 53829 90519733
Menopausal symptoms 18.15 14.06 15 54870 3063 90570499
Hepatic mass 18.07 14.06 13 54872 2164 90571398
Heart rate decreased 18.07 14.06 5 54880 53500 90520062
Hypernatraemia 17.72 14.06 25 54860 9362 90564200
Hydronephrosis 17.69 14.06 29 54856 12373 90561189
Metastatic neoplasm 17.68 14.06 18 54867 4797 90568765
Bone marrow tumour cell infiltration 17.60 14.06 4 54881 26 90573536
Breast mass 17.59 14.06 25 54860 9422 90564140
Loose tooth 17.54 14.06 16 54869 3727 90569835
Radiation pneumonitis 17.53 14.06 12 54873 1846 90571716
Thoracic vertebral fracture 17.49 14.06 19 54866 5455 90568107
Coeliac disease 17.43 14.06 3 54882 44607 90528955
Bronchitis 17.43 14.06 42 54843 152885 90420677
Musculoskeletal chest pain 17.40 14.06 42 54843 23708 90549854
Wound treatment 17.39 14.06 6 54879 199 90573363
Vertigo 17.36 14.06 86 54799 69725 90503837
Progesterone receptor assay positive 17.35 14.06 7 54878 361 90573201
Metastases to eye 17.28 14.06 6 54879 203 90573359
Sedation 17.23 14.06 4 54881 48167 90525395
Water intoxication 17.21 14.06 8 54877 583 90572979
Carcinoembryonic antigen increased 17.18 14.06 13 54872 2337 90571225
Dry mouth 16.95 14.06 56 54829 184003 90389559
Intestinal metastasis 16.90 14.06 6 54879 217 90573345
Pustule 16.89 14.06 14 54871 2869 90570693
Metastases to bone marrow 16.86 14.06 8 54877 611 90572951
Dry skin 16.85 14.06 101 54784 87972 90485590
Fractured sacrum 16.81 14.06 13 54872 2414 90571148
Congenital haematological disorder 16.55 14.06 4 54881 35 90573527
Metastases to bladder 16.47 14.06 6 54879 234 90573328
Ocular vasculitis 16.40 14.06 5 54880 111 90573451
Oral herpes 16.29 14.06 51 54834 33473 90540089
Hyperbaric oxygen therapy 16.26 14.06 4 54881 38 90573524
Uterine polyp 16.20 14.06 13 54872 2547 90571015
Therapy non-responder 16.01 14.06 37 54848 136667 90436895
Fingerprint loss 15.98 14.06 4 54881 41 90573521
Ascariasis 15.94 14.06 3 54882 6 90573556
Red blood cell sedimentation rate increased 15.79 14.06 16 54869 82579 90490983
Night sweats 15.78 14.06 34 54851 128732 90444830
Osteoarthritis 15.74 14.06 63 54822 195667 90377895
Peliosis hepatis 15.69 14.06 5 54880 129 90573433
Bone marrow failure 15.64 14.06 49 54836 32172 90541390
Hydrothorax 15.62 14.06 9 54876 1024 90572538
Fistula 15.56 14.06 27 54858 12062 90561500
Disability 15.36 14.06 3 54882 40742 90532820
Aortic arteriosclerosis 15.30 14.06 21 54864 7663 90565899
Pulmonary fibrosis 15.25 14.06 26 54859 107477 90466085
Lymphopenia 15.22 14.06 39 54846 22842 90550720
Breath odour 15.20 14.06 10 54875 1441 90572121
Coma 15.15 14.06 13 54872 72619 90500943
Pleural mass 15.08 14.06 3 54882 9 90573553
Neutrophil count increased 14.97 14.06 35 54850 19355 90554207
Metastases to ovary 14.94 14.06 7 54878 520 90573042
Bundle branch block left 14.88 14.06 21 54864 7864 90565698
Infection 14.78 14.06 144 54741 361950 90211612
Biopsy site unspecified abnormal 14.78 14.06 4 54881 57 90573505
Heart rate irregular 14.75 14.06 40 54845 24228 90549334
Hypertension 14.72 14.06 192 54693 457340 90116222
Wrong technique in product usage process 14.70 14.06 13 54872 71558 90502004
Poor peripheral circulation 14.70 14.06 15 54870 4010 90569552
Immunodeficiency 14.67 14.06 4 54881 43230 90530332
Abscess oral 14.47 14.06 10 54875 1562 90572000
Portal hypertension 14.47 14.06 16 54869 4685 90568877
Jaundice 14.47 14.06 48 54837 32469 90541093
Metastases to pancreas 14.46 14.06 6 54879 333 90573229
Ostectomy 14.41 14.06 3 54882 12 90573550
Pneumonitis chemical 14.35 14.06 6 54879 339 90573223
Enterocolitis 14.26 14.06 24 54861 10466 90563096
Left ventricular dysfunction 14.20 14.06 29 54856 14640 90558922
Blood pressure fluctuation 14.17 14.06 7 54878 52406 90521156

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute promyelocytic leukaemia 98.34 32.64 15 447 721 42620152

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 1195.08 14.73 447 40828 30925 110517099
Malignant neoplasm progression 1099.58 14.73 728 40547 173839 110374185
Neoplasm progression 852.42 14.73 436 40839 64159 110483865
Metastases to liver 847.91 14.73 361 40914 35025 110512999
Osteonecrosis of jaw 558.58 14.73 298 40977 47719 110500305
Breast cancer metastatic 442.56 14.73 164 41111 11017 110537007
Disease progression 430.91 14.73 492 40783 243542 110304482
Metastases to lung 416.26 14.73 193 41082 22870 110525154
Metastases to lymph nodes 329.15 14.73 144 41131 14888 110533136
Tumour marker increased 298.94 14.73 100 41175 4960 110543064
Metastases to skin 230.25 14.73 68 41207 2231 110545793
Stomatitis 221.86 14.73 377 40898 269865 110278159
Pneumonitis 216.21 14.73 199 41076 76332 110471692
Mucosal inflammation 202.63 14.73 213 41062 95928 110452096
Breast cancer 200.01 14.73 143 41132 38399 110509625
Bone pain 198.99 14.73 177 41098 64956 110483068
Hot flush 166.03 14.73 161 41114 65875 110482149
Breast cancer recurrent 158.02 14.73 58 41217 3788 110544236
Pleural effusion 157.87 14.73 257 41018 177452 110370572
Lymphoedema 157.74 14.73 87 41188 14842 110533182
Fatigue 144.28 14.73 858 40417 1215100 109332924
Osteonecrosis 138.95 14.73 109 41166 33632 110514392
PIK3CA-activated mutation 133.14 14.73 34 41241 639 110547385
Bone disorder 129.60 14.73 87 41188 21105 110526919
Bone lesion 117.63 14.73 56 41219 7031 110540993
Second primary malignancy 112.47 14.73 75 41200 17993 110530031
Ejection fraction decreased 109.05 14.73 103 41172 40777 110507247
Drug ineffective 108.90 14.73 256 41019 1520284 109027740
Off label use 107.89 14.73 252 41023 1499933 109048091
Neuropathy peripheral 107.86 14.73 219 41056 179058 110368966
Carbohydrate antigen 15-3 increased 104.31 14.73 34 41241 1553 110546471
Metastases to pleura 103.20 14.73 36 41239 2027 110545997
Cough 102.30 14.73 391 40884 461250 110086774
Pseudocirrhosis 95.50 14.73 28 41247 895 110547129
Neutropenia 95.38 14.73 332 40943 374288 110173736
Exposed bone in jaw 88.28 14.73 38 41237 3773 110544251
Metastases to spine 88.01 14.73 42 41233 5301 110542723
Pleural neoplasm 87.25 14.73 22 41253 392 110547632
Metastases to central nervous system 86.02 14.73 70 41205 22747 110525277
Ascites 82.04 14.73 134 41141 92674 110455350
Maternal exposure during pregnancy 81.86 14.73 3 41272 254880 110293144
Device related thrombosis 78.49 14.73 34 41241 3428 110544596
Palmar-plantar erythrodysaesthesia syndrome 77.79 14.73 86 41189 40939 110507085
White blood cell count decreased 77.29 14.73 224 41051 229166 110318858
Infusion related reaction 75.72 14.73 24 41251 381138 110166886
Hormone receptor positive breast cancer 75.40 14.73 21 41254 556 110547468
Tooth extraction 73.88 14.73 51 41224 12940 110535084
Hypotension 73.58 14.73 53 41222 523796 110024228
Rheumatoid arthritis 73.16 14.73 12 41263 299601 110248423
Interstitial lung disease 71.96 14.73 160 41115 139174 110408850
Therapeutic product effect decreased 71.76 14.73 5 41270 244311 110303713
Hepatic lesion 69.72 14.73 42 41233 8451 110539573
Metastases to the mediastinum 68.80 14.73 21 41254 772 110547252
Myelosuppression 67.42 14.73 124 41151 94216 110453808
Diarrhoea 65.70 14.73 681 40594 1138824 109409200
Metastases to peritoneum 62.88 14.73 34 41241 5576 110542448
Psoriatic arthropathy 60.90 14.73 3 41272 196758 110351266
Contraindicated product administered 58.30 14.73 11 41264 248256 110299768
Metastasis 58.02 14.73 37 41238 8230 110539794
Asthenia 57.18 14.73 446 40829 688553 109859471
Oral pain 56.80 14.73 70 41205 37374 110510650
Arthralgia 55.78 14.73 488 40787 779144 109768880
Joint swelling 55.66 14.73 50 41225 442795 110105229
Lymphadenopathy mediastinal 55.31 14.73 31 41244 5453 110542571
Lymphangiosis carcinomatosa 55.04 14.73 24 41251 2458 110545566
Synovitis 54.88 14.73 17 41258 274075 110273949
Drug abuse 53.98 14.73 3 41272 177408 110370616
Intentional product use issue 52.16 14.73 14 41261 247892 110300132
Aphthous ulcer 52.10 14.73 51 41224 21085 110526939
Malignant pleural effusion 52.08 14.73 27 41248 4066 110543958
Wound 51.73 14.73 12 41263 234425 110313599
Decreased appetite 50.48 14.73 327 40948 475519 110072505
Blood alkaline phosphatase increased 50.37 14.73 93 41182 70842 110477182
Irritable bowel syndrome 49.28 14.73 3 41272 164212 110383812
Bone sequestrum 48.46 14.73 18 41257 1215 110546809
Gingival swelling 48.04 14.73 28 41247 5302 110542722
Overdose 47.71 14.73 14 41261 233780 110314244
Hyperglycaemia 47.67 14.73 101 41174 84989 110463035
Nail disorder 47.64 14.73 81 41194 57854 110490170
Peritoneal disorder 47.50 14.73 16 41259 810 110547214
Invasive ductal breast carcinoma 47.27 14.73 30 41245 6616 110541408
Nausea 46.60 14.73 682 40593 1235008 109313016
Glossodynia 45.84 14.73 13 41262 221991 110326033
Haematotoxicity 44.89 14.73 47 41228 21035 110526989
Confusional state 44.74 14.73 66 41209 468614 110079410
Fibromyalgia 43.65 14.73 6 41269 170903 110377121
Pathological fracture 43.44 14.73 36 41239 11996 110536028
Folliculitis 42.54 14.73 6 41269 167647 110380377
Oral cavity fistula 42.26 14.73 14 41261 673 110547351
Skin toxicity 42.01 14.73 35 41240 11748 110536276
Osteolysis 41.97 14.73 26 41249 5497 110542527
Mobility decreased 40.41 14.73 19 41256 237403 110310621
Discomfort 40.05 14.73 15 41260 214692 110333332
Toxicity to various agents 38.23 14.73 76 41199 480479 110067545
Dysgeusia 37.97 14.73 82 41193 69903 110478121
Epistaxis 37.95 14.73 121 41154 130251 110417773
Nail dystrophy 37.78 14.73 15 41260 1213 110546811
Osteitis 37.23 14.73 22 41253 4274 110543750
Creutzfeldt-Jakob disease 37.20 14.73 10 41265 231 110547793
Amaurosis fugax 36.98 14.73 18 41257 2372 110545652
Hydrothorax 36.66 14.73 16 41259 1642 110546382
Arthropathy 36.66 14.73 32 41243 287490 110260534
Superinfection 36.05 14.73 24 41251 5739 110542285
Sequestrectomy 35.80 14.73 13 41262 823 110547201
Type 2 diabetes mellitus 35.45 14.73 11 41264 177221 110370803
Product use in unapproved indication 35.37 14.73 71 41204 447306 110100718
Mouth ulceration 35.30 14.73 64 41211 48074 110499950
Abdominal lymphadenopathy 35.16 14.73 16 41259 1812 110546212
Lacrimation increased 34.83 14.73 50 41225 30900 110517124
Metastases to chest wall 34.60 14.73 12 41263 664 110547360
Blister 34.59 14.73 21 41254 227355 110320669
Bradycardia 34.22 14.73 8 41267 155509 110392515
Treatment failure 33.98 14.73 32 41243 277202 110270822
Metastases to soft tissue 33.87 14.73 12 41263 707 110547317
Metastases to eye 33.86 14.73 10 41265 328 110547696
Trigger finger 33.78 14.73 22 41253 5070 110542954
Urinary tract disorder 33.37 14.73 23 41252 5821 110542203
Nail infection 33.36 14.73 17 41258 2471 110545553
Wheezing 33.03 14.73 28 41247 255202 110292822
Therapeutic product effect incomplete 32.23 14.73 22 41253 223783 110324241
Weight increased 31.98 14.73 68 41207 419576 110128448
Gingival recession 31.23 14.73 14 41261 1532 110546492
Exostosis of jaw 30.88 14.73 13 41262 1222 110546802
Intentional overdose 30.82 14.73 6 41269 132495 110415529
Back pain 30.60 14.73 240 41035 370756 110177268
Tumour marker abnormal 30.56 14.73 9 41266 292 110547732
Injury 30.45 14.73 14 41261 177251 110370773
Axillary pain 29.90 14.73 16 41259 2570 110545454
Pleural disorder 29.36 14.73 12 41263 1047 110546977
Recall phenomenon 29.34 14.73 13 41262 1383 110546641
Weight decreased 29.34 14.73 285 40990 467772 110080252
Pulmonary mass 29.16 14.73 51 41224 37250 110510774
Pain in jaw 28.95 14.73 61 41214 51116 110496908
Breast mass 28.65 14.73 24 41251 8117 110539907
Aspartate aminotransferase increased 28.63 14.73 127 41148 159809 110388215
Acute promyelocytic leukaemia 28.50 14.73 14 41261 1882 110546142
Fibrous histiocytoma 28.46 14.73 11 41264 828 110547196
Condition aggravated 28.20 14.73 160 41115 734676 109813348
Hepatic function abnormal 27.94 14.73 85 41190 89210 110458814
Lymphadenopathy 27.17 14.73 68 41207 63767 110484257
Hypersensitivity 27.15 14.73 70 41205 403928 110144096
Lip dry 26.80 14.73 3 41272 100080 110447944
Abdominal discomfort 26.65 14.73 68 41207 393790 110154234
Obesity 26.65 14.73 5 41270 113346 110434678
Urticaria 26.59 14.73 49 41226 318808 110229216
Anaemia 26.34 14.73 316 40959 546770 110001254
Gastrointestinal disorder 26.20 14.73 31 41244 241921 110306103
Medication error 26.20 14.73 4 41271 105362 110442662
Hepatic enzyme increased 26.15 14.73 50 41225 320842 110227182
Muscle twitching 26.14 14.73 43 41232 29892 110518132
Gamma-glutamyltransferase increased 25.77 14.73 65 41210 61244 110486780
Recurrent cancer 25.72 14.73 16 41259 3407 110544617
Joint range of motion decreased 25.39 14.73 7 41268 121825 110426199
Radioisotope scan 25.34 14.73 4 41271 3 110548021
Eastern Cooperative Oncology Group performance status worsened 25.19 14.73 15 41260 2954 110545070
Hallucination 24.88 14.73 4 41271 101428 110446596
Menopausal symptoms 24.85 14.73 14 41261 2487 110545537
Metastases to pelvis 24.80 14.73 10 41265 842 110547182
Osteomyelitis 24.75 14.73 47 41228 36553 110511471
Metastases to abdominal cavity 24.51 14.73 10 41265 868 110547156
Mouth swelling 24.48 14.73 21 41254 7333 110540691
Alanine aminotransferase increased 24.38 14.73 134 41141 183639 110364385
Bursitis 24.35 14.73 9 41266 129909 110418115
Leukopenia 24.29 14.73 115 41160 148676 110399348
Anticipatory anxiety 24.18 14.73 11 41264 1245 110546779
Oral herpes 23.99 14.73 46 41229 36034 110511990
Progesterone receptor assay positive 23.72 14.73 7 41268 229 110547795
Hyperparathyroidism secondary 23.71 14.73 15 41260 3289 110544735
Bone neoplasm 23.70 14.73 10 41265 945 110547079
Blood bilirubin increased 23.47 14.73 72 41203 75900 110472124
Product administered at inappropriate site 23.45 14.73 18 41257 5375 110542649
Cell marker increased 23.36 14.73 9 41266 672 110547352
Radiation fibrosis 23.28 14.73 5 41270 42 110547982
Subclavian vein thrombosis 23.23 14.73 14 41261 2818 110545206
Dyspnoea 23.13 14.73 558 40717 1106314 109441710
Pancreatic neoplasm 23.09 14.73 12 41263 1817 110546207
Hepatic failure 22.99 14.73 67 41208 68672 110479352
Skin mass 22.92 14.73 23 41252 9793 110538231
COVID-19 22.88 14.73 35 41240 245025 110302999
Hepatic atrophy 22.69 14.73 8 41267 465 110547559
Breast pain 22.56 14.73 23 41252 9977 110538047
Metastases to meninges 22.05 14.73 17 41258 5111 110542913
Acute kidney injury 21.93 14.73 143 41132 635287 109912737
Blood phosphorus decreased 21.76 14.73 20 41255 7645 110540379
Neoplasm recurrence 21.74 14.73 17 41258 5215 110542809
Pulmonary tumour thrombotic microangiopathy 21.65 14.73 6 41269 156 110547868
Gait inability 21.58 14.73 12 41263 136364 110411660
Alopecia 21.34 14.73 219 41056 364534 110183490
Blood glucose increased 21.33 14.73 102 41173 132394 110415630
Cutaneous sarcoidosis 21.27 14.73 8 41267 559 110547465
Psoriasis 21.18 14.73 13 41262 139980 110408044
Protein total decreased 20.93 14.73 23 41252 10867 110537157
Hospitalisation 20.52 14.73 14 41261 142479 110405545
Swelling 20.51 14.73 65 41210 350976 110197048
Pustule 20.50 14.73 14 41261 3490 110544534
Poor peripheral circulation 20.46 14.73 15 41260 4182 110543842
Debridement 19.96 14.73 11 41264 1872 110546152
Nipple exudate bloody 19.83 14.73 5 41270 89 110547935
Carcinoid tumour pulmonary 19.69 14.73 7 41268 417 110547607
Periodontitis 19.67 14.73 16 41259 5192 110542832
Adverse event 19.63 14.73 8 41267 108801 110439223
Drug ineffective for unapproved indication 19.48 14.73 7 41268 102831 110445193
Myocardial infarction 19.35 14.73 26 41249 192057 110355967
Periodontal disease 19.23 14.73 11 41264 2011 110546013
Fractured sacrum 19.16 14.73 11 41264 2025 110545999
Insomnia 18.99 14.73 212 41063 360378 110187646
Febrile neutropenia 18.97 14.73 58 41217 316709 110231315
Cholestasis 18.87 14.73 60 41215 64458 110483566
Heart rate decreased 18.72 14.73 4 41271 82752 110465272
Drug interaction 18.57 14.73 110 41165 500073 110047951
Congenital haematological disorder 18.48 14.73 4 41271 35 110547989
Rhabdomyolysis 18.47 14.73 11 41264 120390 110427634
Metastases to thorax 18.20 14.73 6 41269 284 110547740
Red blood cell count decreased 18.11 14.73 60 41215 65863 110482161
Incorrect dose administered 18.09 14.73 8 41267 103633 110444391
Skin lesion 17.92 14.73 51 41224 51580 110496444
Liver injury 17.68 14.73 18 41257 150395 110397629
Road traffic accident 17.65 14.73 9 41266 107389 110440635
Mucosal ulceration 17.57 14.73 11 41264 2368 110545656
Congestive cardiomyopathy 17.53 14.73 24 41251 14195 110533829
Oral disorder 17.50 14.73 22 41253 11981 110536043
Ascariasis 17.39 14.73 3 41272 6 110548018
Osteosclerosis 17.33 14.73 14 41261 4501 110543523
Hypokalaemia 17.27 14.73 122 41153 182326 110365698
Water intoxication 17.21 14.73 8 41267 951 110547073
Lung infiltration 17.12 14.73 32 41243 24596 110523428
Teeth brittle 17.08 14.73 7 41268 615 110547409
Osteopenia 16.88 14.73 30 41245 22179 110525845
Injection site erythema 16.86 14.73 7 41268 94169 110453855
Computerised tomogram abnormal 16.82 14.73 13 41262 3923 110544101
Gingivitis 16.78 14.73 20 41255 10311 110537713
Tumour marker decreased 16.76 14.73 4 41271 56 110547968
Chronic obstructive pulmonary disease 16.71 14.73 10 41265 109148 110438876
Rib fracture 16.55 14.73 38 41237 33732 110514292
Migraine 16.52 14.73 24 41251 171628 110376396
Suicide attempt 16.50 14.73 9 41266 103385 110444639
Peliosis hepatis 16.17 14.73 5 41270 192 110547832
Vulvovaginal dryness 16.13 14.73 11 41264 2736 110545288
Injection site pain 16.05 14.73 26 41249 177896 110370128
Neuromuscular toxicity 16.01 14.73 6 41269 415 110547609
Bone debridement 16.00 14.73 6 41269 416 110547608
Upper respiratory fungal infection 15.93 14.73 6 41269 421 110547603
Mucosal dryness 15.90 14.73 13 41262 4250 110543774
Antinuclear antibody increased 15.66 14.73 8 41267 1168 110546856
Polyneuropathy 15.66 14.73 36 41239 31976 110516048
Pericardial effusion 15.64 14.73 52 41223 57165 110490859
Fluid retention 15.36 14.73 8 41267 94299 110453725
Sinusitis 15.26 14.73 58 41217 296630 110251394
Incorrect product formulation administered 15.24 14.73 5 41270 233 110547791
Heart rate irregular 15.10 14.73 37 41238 34237 110513787
Hormone receptor positive HER2 negative breast cancer 15.08 14.73 5 41270 241 110547783
Sensory loss 15.06 14.73 28 41247 21429 110526595
Oedema peripheral 14.99 14.73 188 41087 328472 110219552
Musculoskeletal chest pain 14.74 14.73 33 41242 28814 110519210

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BG06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Aromatase inhibitors
FDA MoA N0000175080 Aromatase Inhibitors
FDA EPC N0000175563 Aromatase Inhibitor
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D004965 Estrogen Antagonists
MeSH PA D006727 Hormone Antagonists
MeSH PA D047072 Aromatase Inhibitors
MeSH PA D065088 Steroid Synthesis Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:50113 androgen
CHEBI has role CHEBI:50790 EC 1.14.14.14 (aromatase) inhibitor
CHEBI has role CHEBI:78298 environmental contaminant

Related Drugs by ATC class:

L02BG Aromatase inhibitors 5 drugs
aminoglutethimideanastrozoleformestaneletrozolevorozole

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hormone receptor positive malignant neoplasm of breast indication 417181009
Advanced Breast Cancer Progression Post-Antiestrogen Therapy indication
Prevention of Breast Carcinoma off-label use
Pregnancy, function contraindication 289908002
Osteopenia contraindication 312894000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Aromatase Enzyme INHIBITOR IC50 5.69 WOMBAT-PK CHEMBL
Androgen receptor Nuclear hormone receptor WOMBAT-PK
Aromatase Enzyme IC50 7.52 CHEMBL

External reference:

IDSource
4021191 VUID
N0000148637 NUI
D00963 KEGG_DRUG
4021191 VANDF
C0851344 UMLSCUI
CHEBI:4953 CHEBI
EXM PDB_CHEM_ID
CHEMBL1200374 ChEMBL_ID
DB00990 DRUGBANK_ID
C056516 MESH_SUPPLEMENTAL_RECORD_UI
60198 PUBCHEM_CID
7073 IUPHAR_LIGAND_ID
6770 INN_ID
NY22HMQ4BX UNII
258494 RXNORM
180650 MMSL
31449 MMSL
8478 MMSL
d04461 MMSL
007997 NDDF
116115004 SNOMEDCT_US
387017005 SNOMEDCT_US
NY22HMQ4BX INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Aromasin HUMAN PRESCRIPTION DRUG LABEL 1 0009-7663 TABLET 25 mg ORAL NDA 29 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 0832-0595 TABLET 25 mg ORAL ANDA 27 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 44278-025 TABLET 25 mg ORAL ANDA 26 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 50090-5193 TABLET 25 mg ORAL ANDA 26 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 51991-005 TABLET, FILM COATED 25 mg ORAL ANDA 31 sections
Aromasin HUMAN PRESCRIPTION DRUG LABEL 1 54868-5261 TABLET 25 mg ORAL NDA 13 sections
Exemestane Human Prescription Drug Label 1 59651-516 TABLET, FILM COATED 25 mg ORAL ANDA 26 sections
EXEMESTANE HUMAN PRESCRIPTION DRUG LABEL 1 59762-2858 TABLET, SUGAR COATED 25 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 63629-2056 TABLET, FILM COATED 25 mg ORAL ANDA 30 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 68382-383 TABLET 25 mg ORAL ANDA 25 sections
EXEMESTANE HUMAN PRESCRIPTION DRUG LABEL 1 69097-316 TABLET 25 mg ORAL ANDA 23 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 70771-1374 TABLET 25 mg ORAL ANDA 1 sections
Exemestane HUMAN PRESCRIPTION DRUG LABEL 1 71921-190 TABLET, FILM COATED 25 mg ORAL ANDA 28 sections
Exemestane Human Prescription Drug Label 1 72603-329 TABLET, FILM COATED 25 mg ORAL ANDA 26 sections